Edit ID | Edit Comment | Time | |
---|
402678 | New Interpretation | 01/22/2019 1:33 PM |
Before
The interpretation was not yet created, or had been deleted.After (Current Version)
Tier 2InterpretationSomatic mutations in PIK3CA have been found in 10--30% of colorectal cancers. KRAS, NRAS, BRAF and PIK3CA and non-functional PTEN predict resistance to anti-EGFR therapies in metastatic colorectal cancer. Recent 'molecular pathological epidemiology' (MPE) research has shown that aspirin use may be associated with better prognosis and clinical outcome in PIK3CA-mutated colorectal carcinoma, suggesting somatic PIK3CA mutation may be a molecular biomarker that predicts response to aspirin therapy. The R88Q mutation falls within the ABD domain of the p110a catalytic subunit and has been shown to result in gain-of-function in vitro. PIK3CA may be a target of directed therapy in some clinical settings.
|
Citations- Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations
- mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110a (PIK3CA). Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15259-64.
- Samuels Y, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554
- Therkildsen C, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53(7):852-64
- Liao RG, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013;73(16):5195-205
- Ogino S, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014;33(23):2949-55
|
Last updated: 2019-01-22 18:33:24 UTC
|